BioInvent (Sweden)

BioInvent (Sweden)

BioInvent International is a Swedish clinical-stage biotech company that discovers and develops novel and first-in-class immunomodulatory antibodies for cancer therapy. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for BioInvent (Sweden), Sweden, covering academic research published from 2000 to 2024. Read More.


Open Access Percentage

47%


Total
Publications

114


Total Open
Publications

54


Total
Citations

4.2K


Open Access
Percentage

47%


Total
Publications

114


Total Open
Publications

54


Total
Citations

4.2K

Wikipedia

Website

download

Breakdown

20% 24% 4% 52%

Publisher Open

20%

Both

24%

Other Platform Open

4%

Closed

52%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

0123456789101112Total Publications
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Open

Closed

Publisher Open

53%OA Journal

OA Journal 53%

27

Hybrid 22%

11

No Guarantees 25%

13

Other Platform Open

Domain 76%

25

Institution 30%

10

Other Internet 12%

4

Preprint 6%

2

Public 6%

2

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
25
DOI
Other Internet
4
University of Cambridge
Institution
3
Figshare
Public
3
Europe PMC
Domain
3
bioRxiv
Preprint
2
ZB MED - Information Centre for Life Sciences
Institution
1
University of Leicester
Institution
1
University of Bath
Institution
1
University College of Arts Crafts and Design
Institution
1
1 / 2

Data updated 18 August 2025

Share

Share

Share